Stanford Research Unveils Natural Molecule BRP, a Potential Ozempic Alternative

Discovery of BRP: A Natural Alternative to Semaglutide

Researchers at Stanford Medicine have made a significant advancement in the search for effective weight loss solutions. Their studies reveal a naturally occurring molecule named BRP, which demonstrates ability to replicate the weight loss benefits of semaglutide, commonly known as Ozempic. In initial animal studies, BRP successfully reduced both appetite and body weight, all while sidestepping the typical adverse effects such as nausea and muscle loss that often accompany conventional treatments.

Mechanism of Action

BRP operates through a distinct biological mechanism, specifically targeting the hypothalamus, the brain region responsible for regulating appetite and metabolism. Assistant Professor Katrin Svensson, a crucial contributor to this research, emphasizes that while semaglutide influences receptors found throughout the brain, gut, and pancreas, BRP’s focused action may enhance precision in appetite control.

Intelligent Design: AI in Research

The discovery hinged on innovative technology, particularly artificial intelligence, which assisted in sifting through a vast array of molecules known as prohormones. These initially inactive molecules can be fragmented into peptides, which are vital for metabolic processes in the brain and throughout the body. Traditional laboratory methods often struggle to identify functional peptides hidden among numerous inactive fragments, making this search challenging.

Targeting Prohormones with Precision

The research team devised a computer algorithm named Peptide Predictor. This tool scanned approximately 20,000 human protein-coding genes to pinpoint optimal sites for cutting prohormones into therapeutically useful peptides. By concentrating on proteins capable of secretion outside cells, they narrowed their focus to 373 prohormones that were poised for further investigation.

Experimental Findings

Following this initial screening, the team identified a staggering 2,683 potential peptides, culminating in the testing of 100 diverse candidates, including GLP-1. Findings showed that while GLP-1 had a positive influence on neuronal activity, BRP—comprising only 12 amino acids—exceeded expectations, enhancing neuronal response more than tenfold compared to control samples.

Positive Weight Loss Outcomes in Trials

Putting BRP to the test in lean mice and minipigs, which provide a more accurate representation of human metabolic responses, yielded impressive results. A single dose delivered before feeding led to a remarkable 50% decrease in food intake within one hour. Furthermore, in a two-week trial involving obese mice, daily injections resulted in an average weight loss of 3 grams, primarily consisting of fat. Notably, the control group of untreated mice actually gained about 3 grams over the same period.

Reassuring Safety Profile

Crucially, these experiments revealed no adverse impacts on movement, water intake, or other behavioral metrics. Further analyses indicated that BRP functions through entirely separate metabolic pathways compared to GLP-1 and semaglutide, raising hopes for a treatment with minimal side effects.

Looking Ahead: Future Applications

The research team is now dedicated to identifying the specific receptors that interact with BRP, aiming to elucidate its comprehensive operating mechanisms within the body. There's also a concerted effort to extend its therapeutic effects, enhancing usability for potential human applications if BRP proves effective.

Collaboration across Institutions

This groundbreaking work involved collaboration among Stanford researchers and teams from the University of California, Berkeley, the University of Minnesota, and the University of British Columbia, emphasizing a community-driven approach to solving a pressing medical issue. Funding for the study came from multiple sources, including the National Institutes of Health and various academic programs.

Both Svensson and Coassolo, the study's lead author, are listed as inventors on emerging patents related to BRP's applications for metabolic disorders and are also co-founders of a new venture, Merrifield Therapeutics, which plans to initiate human clinical trials in the near future.

The scientific community now eagerly anticipates further developments regarding BRP's safety and efficacy in human subjects, as a safe and effective alternative to existing obesity treatments could have a transformative impact on public health.

Materials provided by Stanford Medicine. Note: Content may be edited for style and length.